Immunology Biosimilars Market Expansion Outlook: $13.57 Billion by 2029 Forecast

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Predicted Market Size Trajectory For The Immunology Biosimilars Market From 2025 To 2034?

The size of the immunology biosimilars market has experienced rapid expansion over recent years. This market is projected to expand from $7.38 billion in 2024 to $8.35 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 13.1%. Factors contributing to its historical growth include the greater acceptance of biosimilars, a rising need for affordable biologics, an increase in autoimmune disease cases, broader patient understanding of biosimilar treatments, and enhanced regulatory backing for biosimilar authorizations.

The immunology biosimilars market is projected to experience substantial expansion in the coming years, with its valuation anticipated to reach $13.57 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 12.9%. This growth during the forecast period is attributable to an increased emphasis on curbing healthcare costs, the escalating incidence of chronic inflammatory conditions, deeper market penetration in emerging regions, broadened support for biosimilar interchangeability, and heightened investments from pharmaceutical firms. Key trends anticipated within the same period encompass advancements in biologics manufacturing technologies, collaborative efforts in research and development, the creation of next-generation biosimilars, breakthroughs in drug delivery mechanisms, and the integration of artificial intelligence into biosimilar development processes.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25789&type=smp

What Are The Main Drivers Boosting The Immunology Biosimilars Industry’s Expansion?

A rising incidence of chronic immunological conditions is projected to drive the expansion of the immunology biosimilars market in the foreseeable future. These long-term conditions involve the immune system malfunctioning, either by attacking the body’s own tissues or by being unable to provide effective protection. This increase in chronic immunological conditions stems from a growing population suffering from enduring immune system disorders, necessitating continuous therapeutic interventions, proactive disease management, and persistent healthcare assistance. Immunology biosimilars aid in managing chronic immunological conditions by offering cost-effective and efficient treatment alternatives, facilitating sustained disease management, and enhancing patient access to vital therapies designed to regulate immune system dysfunction. For example, in June 2024, data from the Australian Institute of Health and Welfare, an Australia-based government organization, indicated that rheumatoid arthritis, a systemic autoimmune disease, impacted approximately 514,000 people (2.0%) in 2022, comprising 2.5% of females and 1.6% of males afflicted by the condition. Consequently, the escalating occurrence of chronic immunological conditions is fueling expansion within the immunology biosimilars market.

What Are The Major Segments Identified In The Immunology Biosimilars Market?

The immunology biosimilars market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibodies, Fusion Proteins, Recombinant Proteins, Interferons, Other Biosimilar Immunomodulators

2) By Disease: Inflammatory Bowel Disease, Arthritis, Other Diseases

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By End User: Hospitals, Clinics, Homecare Settings, Ambulatory Surgical Centers (ASCs)

Subsegments:

1) By Monoclonal Antibodies: Anti-Tumor Necrosis Factor Agents, Anti-Interleukin-6 Agents, Anti-Cluster of Differentiation 20 Agents, Anti-Interleukin-12/23 Agents, Other Monoclonal Antibodies

2) By Fusion Proteins: Etanercept Biosimilars, Other Fusion Protein Biosimilars

3) By Recombinant Proteins: Recombinant Human Insulin, Recombinant Human Growth Hormone, Recombinant Human Erythropoietin, Other Recombinant Protein Biosimilars

4) By Interferons: Interferon Alpha, Interferon Beta, Interferon Gamma

5) By Other Biosimilar Immunomodulators: Interleukin Inhibitors, Janus Kinase Inhibitors, Other Immunomodulatory Biosimilars

What Long-Term Trends Will Shape The Future Growth Of The Immunology Biosimilars Industry?

Leading corporations within the immunology biosimilars market are concentrating on developing advanced biosimilar innovations, such as an anticipated interchangeability designation, improved formulations with greater stability, and novel delivery methods, aiming to offer patients more accessible and effective treatment alternatives. An anticipated interchangeability designation indicates that the biosimilar is projected to fulfill regulatory criteria, enabling its substitution for the reference biologic directly at the pharmacy without requiring prescriber involvement. As an example, in February 2025, Sandoz Group AG, a pharmaceutical firm based in Switzerland, introduced Pyzchiva (ustekinumab-ttwe), a biosimilar counterpart to Stelara, intended for managing chronic autoimmune conditions including plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. This launch, executed in collaboration with Samsung Bioepis Co. Ltd., a biopharmaceutical company from South Korea, underscores Sandoz’s dedication to broadening patient access to immunology biosimilars through a cost-effective and patient-focused treatment that provides various dosing options, enhanced stability, and the unique feature of being able to be re-refrigerated following initial cooling.

Which Key Players Are Driving Competition In The Immunology Biosimilars Market?

Major companies operating in the immunology biosimilars market are Pfizer Inc., Novartis AG, LG Chem Ltd., Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., Stada Arzneimittel AG, Cipla Ltd., Kyowa Kirin Co. Ltd., Dr. Reddy’s Laboratories Ltd., Samsung Bioepis Co. Ltd., Gedeon Richter Plc, Celltrion Inc., Biocon Ltd., Innovent Biologics Inc., Biocad, Mabion S.A.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/immunology-biosimilars-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Immunology Biosimilars Market?

North America was the largest region in the immunology biosimilars market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunology biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Immunology Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/customise?id=25789&type=smp

Browse Through More Reports Similar to the Global Immunology Biosimilars Market 2025, By The Business Research Company

Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Bevacizumab Biosimilars Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795